Denmark-based Pharmacosmos A/S on August 7, 2024, entered a merger agreement to acquire G1 Therapeutics Inc. (GTHX) through its U.S. subsidiary Pharmacosmos Therapeutics Inc. for about $405 million.
As per the terms of the agreement, Pharmacosmos will commence a cash tender offer to acquire all issued and outstanding shares of G1 common stock for $7.15 per share in cash, representing a premium of 68.24% from the stock’s last close.